Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas.
Sign Up to like & getrecommendations! Published in 2018 at "Academic radiology"
DOI: 10.1016/j.acra.2017.10.018
Abstract: RATIONALE AND OBJECTIVE The objective of this study was to analyze prognostic factors for survival after transarterial chemoembolization (TACE) combined with sorafenib for hepatocellular carcinoma (HCC) of Barcelona Clinic Liver Cancer (BCLC) stages B and… read more here.
Keywords: combined sorafenib; sorafenib treatment; prognostic factors; bclc stage ... See more keywords
Glutamine synthetase-negative hepatocellular carcinoma has better prognosis and response to sorafenib treatment after hepatectomy.
Sign Up to like & getrecommendations! Published in 2023 at "Chinese medical journal"
DOI: 10.1097/cm9.0000000000002380
Abstract: BACKGROUND Glutamine synthetase (GS) and arginase 1 (Arg1) are widely used pathological markers that discriminate hepatocellular carcinoma (HCC) from intrahepatic cholangiocarcinoma; however, their clinical significance in HCC remains unclear. METHODS We retrospectively analyzed 431 HCC… read more here.
Keywords: treatment hepatectomy; prognosis; hcc; sorafenib treatment ... See more keywords
Abstract 3146: Targeting ANXA3 in combination with sorafenib for the treatment of hepatocellular carcinoma
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-3146
Abstract: Sorafenib is the only FDA-approved tyrosine kinase inhibitor for targeted therapy in advanced HCC. Nevertheless, its efficacy is limited with only a modest improvement in patient outcome, likely due to acquired resistance. In-depth understanding of… read more here.
Keywords: sorafenib treatment; hcc; sorafenib resistant; treatment ... See more keywords
Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment
Sign Up to like & getrecommendations! Published in 2018 at "Liver Cancer"
DOI: 10.1159/000489021
Abstract: Objective: Programmed death-ligand 1 (PD-L1) expression in the tumor microenvironment (TME) has been reported to be related to prognosis in patients with hepatocellular carcinoma (HCC) after hepatectomy. The impact of sorafenib on PD-L1 expression in… read more here.
Keywords: sorafenib treatment; post sorafenib; sorafenib; hcc tissues ... See more keywords
A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation
Sign Up to like & getrecommendations! Published in 2019 at "BMC Cancer"
DOI: 10.1186/s12885-019-5760-8
Abstract: BackgroundPatients with hepatocellular carcinoma waiting for liver transplantation are commonly treated with locoregional treatments, such as TACE and ablation, to prevent tumor progression and dropout and to improve long-term outcome after transplantation. We wanted to… read more here.
Keywords: hepatocellular carcinoma; sorafenib treatment; treatment; liver transplantation ... See more keywords
Expanding Sorafenib Treatment for Hepatocellular Carcinoma Beyond Barcelona Clinic Liver Cancer Stage C Patients: A National Study
Sign Up to like & getrecommendations! Published in 2022 at "AntiCancer Research"
DOI: 10.21873/anticanres.15946
Abstract: Background/Aim: The reimbursement criteria of sorafenib for advanced hepatocellular carcinoma (HCC) were expanded in 2016 by Taiwan’s National Health Insurance (NHI) to include patients without macrovascular invasion or extrahepatic spread. This study explored sorafenib treatment… read more here.
Keywords: hepatocellular carcinoma; sorafenib treatment; treatment; expansion ... See more keywords
Overexpression of PD-L1 is an Independent Predictor for Recurrence in HCC Patients Who Receive Sorafenib Treatment After Surgical Resection
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2021.783335
Abstract: Objective The predicting values of programmed cell death protein 1 (PD-1) and programmed death-ligand 1(PD-L1) were unclear in Hepatocellular carcinoma (HCC) patients who receive sorafenib treatment after curative hepatic resection. Methods We retrospectively enrolled HCC… read more here.
Keywords: hcc patients; sorafenib treatment; recurrence; resection ... See more keywords
Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: Preliminary Toxicity and Activity Data in Dogs
Sign Up to like & getrecommendations! Published in 2020 at "Cancers"
DOI: 10.3390/cancers12051272
Abstract: Unresectable nodular and diffuse hepatocellular carcinoma (HCC) have a poor prognosis with limited treatment options. Systemic traditional chemotherapy has been only rarely reported, with unsatisfactory results. The aim of this prospective, non-randomized, non-blinded, single center… read more here.
Keywords: hepatocellular carcinoma; sorafenib treatment; treatment; unresectable hepatocellular ... See more keywords
PIB: A Score to Select Sorafenib Treatment Candidates for Hepatocellular Carcinoma in Resource-Limited Settings
Sign Up to like & getrecommendations! Published in 2018 at "Hepatitis monthly"
DOI: 10.5812/hepatmon.82345
Abstract: James S Leathers1,*, Domingo Balderramo2, Jhon Prieto3, Fernando Diehl2, Esteban Gonzalez-Ballerga4, Melina R. Ferreiro4, Enrique Carrera5, Fernando Barreyro6, Javier DiazFerrer7, Dupinder Singh8, Angelo Z. Mattos9, Flair Carrilho10, and Jose D. Debes8,** 1School of Medicine, Vanderbilt… read more here.
Keywords: sorafenib treatment; candidates hepatocellular; score select; select sorafenib ... See more keywords